IGF-1 LR3

IGF-1 LR3 (Long R3 IGF-1) is a modified form of insulin-like growth factor 1 with enhanced potency and extended half-life. The modifications prevent IGF binding protein interactions, increasing bioavailability.

Mechanism of Action

IGF-1 LR3 features a 13-amino acid N-terminal extension and an Arg-to-Glu substitution at position 3, dramatically reducing binding to IGF binding proteins. LR3IGF-I infusion stimulates organ growth while reducing plasma IGF binding protein concentrations (Conlon et al., 1995). This results in prolonged activity and enhanced anabolic effects, with LR3IGF-I capable of supporting cell growth at concentrations at least 200-fold lower than required for insulin (Frenkel et al., 2007).

Research Applications

• Enhanced IGF-1 signaling studies (Conlon et al., 1995)
• Cell culture media supplementation (Frenkel et al., 2007)
• IGF binding protein interactions
• Muscle growth and regeneration
• Cell proliferation studies

Product Specifications

• Purity: ≥99% (HPLC verified)
• Molecular Weight: 9111 Da
• Form: Lyophilized powder
• Storage: -20°C

References

1. Conlon MA, et al. "Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig." J Endocrinol. 1995. PMID: 7561636
2. Frenkel J, et al. "LONG R3IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells." Cytotechnology. 2007. PMID: 17172665